These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16327321)

  • 1. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.
    Sabin CA; Smith CJ; Youle M; Lampe FC; Bell DR; Puradiredja D; Lipman MC; Bhagani S; Phillips AN; Johnson MA
    AIDS; 2006 Jan; 20(1):67-71. PubMed ID: 16327321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
    Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
    HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
    Krentz HB; Kliewer G; Gill MJ
    HIV Med; 2005 Mar; 6(2):99-106. PubMed ID: 15807715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of death and factors associated with early death among human immunodeficiency virus (HIV)-infected persons in Singapore: pre-highly active antiretroviral therapy (HAART) and Peri-HAART.
    Chow A; Tey J; Win MK; Leo YS
    Ann Acad Med Singap; 2012 Dec; 41(12):563-70. PubMed ID: 23303113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
    Mzileni MO; Longo-Mbenza B; Chephe TJ
    Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.
    Prins M; Sabin CA; Lee CA; Devereux H; Coutinho RA
    AIDS; 2000 Aug; 14(12):1829-37. PubMed ID: 10985321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
    Brady MT; Oleske JM; Williams PL; Elgie C; Mofenson LM; Dankner WM; Van Dyke RB;
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):86-94. PubMed ID: 20035164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.
    Matinella A; Lanzafame M; Bonometti MA; Gajofatto A; Concia E; Vento S; Monaco S; Ferrari S
    J Neurol; 2015 May; 262(5):1317-27. PubMed ID: 25877836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.
    Pinto AN; Grey P; Shaik A; Cooper DA; Kelleher AD; Petoumenos K
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):936-941. PubMed ID: 29901415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
    Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
    AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.